Fig. 3From: Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot studyIndividual and mean (± standard deviation) values of pulmonary vascular resistance (a) and pulmonary artery systolic pressure (b) at baseline and after 6 months of therapyBack to article page